Article
Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression.
Theranostics - 1 Jan 2020
Gao Qianqian, Ouyang Wenjie, Kang Bin, Han Xu, Xiong Ying, Ding Renpeng, Li Yijian, Wang Fei, Huang Lei, Chen Lei, Wang Dan, Dong Xuan, Zhang Zhao, Li Yanshan, Ze Baichen, Hou Yong, Yang Huanming, Ma Yuanyuan, Gu Ying, Chao Cheng-Chi
Abstract excerpt
Rationale: KRAS is one of the most frequently mutated oncogenes in cancers. The protein's picomolar affinity for GTP/GDP and smooth protein structure resulting in the absence of known allosteric regulatory sites makes its genomic-level activating mutations a difficult but attractive target. Methods: Two CRISPR systems, genome-editing CRISPR/SpCas9 and transcription-regulating dCas9-KRAB, were developed to deplete...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.